Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, Biocon, Celltrion, Dr. Reddy's, Pfizer, Roche, Samsung, Sandoz, Teva, Viatris

globenewswire.com
ABBV AbbVie is mentioned as a leading player in the Middle East and Africa biosimilars market. The article does not provide specific sentiment towards AbbVie's performance or prospects within this market. AMGN Amgen is listed as a leading player in the Middle East and Africa biosimilars market. The article does not offer specific positive or negative sentiment regarding Amgen's position or future in this region. PFE Pfizer is named as a key player in the Middle East and Africa biosimilars market. The article does not express a specific sentiment (bullish or bearish) about Pfizer's role or performance in this market. VTRS Viatris is identified as a leading player in the Middle East and Africa biosimilars market. The article does not provide any specific sentiment or outlook for Viatris within this context.

Middle East and Africa Biosimilars Market Trends Report 2026-2035, Profiles of AbbVie, Amgen, Biocon, Celltrion, Dr. Reddy's, Pfizer, Roche, Samsung, Sandoz, Teva, Viatris Dublin, April 17, 2026 (GLOBE NEWSWIRE) -- The "Middle East and Africa Biosimilars Market: Industry Trends and Global Forecasts - Distribution by Drug Class, Therapeutic Area, Type of Manufacturer, Distribution Channel, Geographical Regions and Leading Players" report has been added to ResearchAndMarkets.com's offering.

The Middle East and Africa biosimilars market is estimated to grow from USD 1.15 billion in the current year to USD 5.73 billion by 2035 at a CAGR of 19% during the forecast period, till 2035.

The biosimilars market in the Middle East and Africa is currently experiencing rapid growth, fueled by increased healthcare investments, a rising prevalence of chronic diseases such as diabetes and cancer, and favorable regulatory environments in prominent countries like Saudi Arabia, the UAE, and South Africa. Particularly in areas with limited resources, the pressing demands created by chronic illnesses like diabetes and cancer necessitate the use of biologics, yet their high costs often leave many patients unable to access them.

The biosimilars market is expected to grow significantly in the upcoming years as patents of biologics expire, paving the way for the introduction of biosimilars that closely mimic their original counterparts. Lately, the biologics sector has experienced considerable expansion, largely due to its increased effectiveness in managing chronic diseases.

Nonetheless, the high costs associated with biologics create major financial and healthcare obstacles. As the demand for biologics continues to increase, developers are exploring innovative approaches to create more affordable biologic products that maintain comparable safety and efficacy standards to optimize their investment returns.

Growth Drivers: Strategic Enablers of Market Expansion

The Middle East and Africa Biosimilars Market experiences robust growth driven by several key factors, including rising prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders and increased demand for affordable biologic alternatives. In addition, government initiatives such as streamlined regulatory pathways for biologics also propel market growth. Further, patent expiries of major drugs like Herceptin and Rituxan, enable local manufacturers to expand portfolios rapidly. Strategic partnerships with global firms, low-cost manufacturing capabilities, and a skilled workforce further position Middle East as one of the leading exporters.

Market Challenges: Critical Barriers Impeding Progress

Challenges persist in the Middle East and Africa Biosimilars Market despite the ongoing market growth, hindering faster adoption. High development costs, complex manufacturing processes requiring stringent quality controls, and risks of immunogenicity or structural variability raise entry barriers for smaller players in this market space. Further, regulatory hurdles, including evolving guidelines and the need for comparative clinical trials, result in delayed approvals. In addition, poor domestic production and R&D infrastructure the region lead to import dependency and supply disruptions. Market access issues, such as competition from branded generics, pricing pressures, and patent litigations from originator companies, also constrain growth.

Monoclonal Antibodies: Leading Market Segment

At present, the monoclonal antibodies segment holds almost 55% of the total market share in Middle East and Africa. This leading position is mainly due to their widespread application in the treatment of chronic illnesses such as cancer, rheumatoid arthritis, and various autoimmune disorders. However, the peptide segment is expected to expand at a faster CAGR throughout the forecast period.

Oncological Disorders: Dominating Market Segment

Currently, oncological disorders dominate the Middle East and Africa Biosimilars Market, capturing most the market share. This trend is further supported by an aging population, changes in lifestyle, and improved diagnostic techniques, necessitating affordable treatments, particularly for costly monoclonal antibody therapies. As a result, this presents attractive growth opportunities for biosimilar developers. Additionally, the hematological disorders segment is expected to experience a higher compound annual growth rate (CAGR) during the forecast period.

Reasons to Buy this Report

Key Attributes:

Key Players in Middle East and Africa Biosimilars Market

Key Segments

By Drug Class

By Therapeutic Area

By Type of Manufacturer

By Distribution Channel

Complementary Benefits

For more information about this report visit https://www.researchandmarkets.com/r/f8skpe

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment